{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Class (Stereo):
CHEMICAL (MIXED)
Bibapcitide, a 26 amino acid, bis-succinimidomethyl ether-linked dimer of the peptide apcitide is a component of lyophilized kit having the trade name AcuTect. When pertechnetate (99mTcO4-) is added to the AcuTect radiopharmaceutical kit and the resulting kit is heated, [99mTcO] apcitide forms. This kit is used for scintigraphic imaging of veins to identify acute venous thrombosis in the lower legs.
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Peforelin, a decapeptide analog of the natural gonadotropin acts as the natural gonadotropin-releasing hormone (GnRH) agonist. This drug under the brand name Maprelin is used in veterinary to stimulate the reproductive function of sows after weaning piglets in the syndrome of sexual depression.
Status:
Investigational
Source:
NCT04083339: Phase 3 Interventional Active, not recruiting Diabetic Cardiomyopathies
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Aldose reductase-IN-1 is an inhibitor of aldose reductase
Status:
Investigational
Source:
INN:evifacotrep [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT02369029: Phase 1 Interventional Terminated Neoplasms
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
INN:ceperognastat [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
INN:solangepras [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT00316797: Phase 1 Interventional Completed Neurodegenerative Diseases
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT04454658: Phase 1 Interventional Active, not recruiting Myelofibrosis (MF)
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT04386980: Phase 3 Interventional Withdrawn Osteoarthritis, Knee
(2021)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Resiniferatoxin (RTX or RTX-107) is a vanilloid derived from a cactus-like plant (Euphoria resiniferous) and has anti-inflammatory activity. This compound is an agonist of the transient receptor potential vanilloid 1 (TRPV1). Resiniferatoxin produces analgesia by desensitizing the TRPV1 receptor. Findings of several studies have suggested a potential therapeutic use of the anti-inflammatory effect of resiniferatoxin. Phase I and II clinical trials have been completed or are underway, evaluating the safety and efficacy of resiniferatoxin in pain-related disorders such as osteoarthritis and cancers.